ArticleFrontiers of medicine2025
A phase 1/2 pilot study of acupuncture and moxibustion at Zusanli (ST36) as a prophylactic treatment in middle-aged and elderly individuals.
Article in Frontiers of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Activating the vagus nerve-adrenal anti-inflammatory axis to delay aging: A randomized controlled trial protocol.Contemporary clinical trials communications · 2026Article
- Effect of electroacupuncture on postoperative delirium in elderly patients undergoing laparoscopic radical prostatectomy: study protocol for a double-center randomized controlled trial.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zusanli (ST36), one of the most essential acupoints in clinical acupuncture practice, is considered as an intervention strategy for disease prevention and longevity promotion in traditional Chinese medicine (TCM). However, the prophylactic effects of ST36 have yet to be investigated in clinical studies. In the present study, we conducted a single-arm, open-label, pilot clinical trial to evaluate the prophylactic effects of stimulating the ST36 acupoint through acupuncture and moxibustion in middle-aged and elderly participants. Of the 85 participants who completed the first 2 months of acupuncture and moxibustion, 48 continued through the remaining 4 months to complete the full 6-month intervention. For 6 months acupuncture and moxibustion at ST36 significantly reduced levels of low-density lipoprotein (LDL) and uric acid (UA) in individuals with initially abnormal LDL and UA values. The median LDL levels decreased from 4.46 mmol/L (IQR 4.32-4.71) to 3.97 mmol/L (IQR 3.32-4.47) (P = 0.004) and the median UA levels decreased from 399.00 µmol/L (IQR 356.00-483.00) to 361.00 µmol/L (IQR 323.00-421.00) (P = 0.003). Additionally, ST36 intervention led to marked reductions in the levels of lactic dehydrogenase (LDH) (266.50 U/L (IQR 257.50-282.25) to 235.50 U/L (IQR 215.50-244.75), P < 0.001) at 6 months, and α-hydroxybutyrate dehydrogenase (α-HBDH) (195.50 U/L (IQR 190.25-212.00) to 181.00 U/L (IQR 165.75-187.25), P = 0.017) at 2 months. Notably, ST36 acupuncture and moxibustion also showed positive effects on sleep quality, knee joint function, and bowel movement patterns, and there were no syncope, severe pain or other adverse reactions. These findings provide clinical evidence that ST36 acupoint stimulation confers holistic health benefits for middle-aged and elderly populations, while maintaining an excellent safety profile.
Indexed as
Identifiers
41402698What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.